Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease.
A new heparinoid, Org 10172, was given to five patients with hemorrhagic stroke with thromboembolic complications. Treatment did not cause progression of cerebral bleeding, and thrombotic processes were inhibited. No side effects were encountered.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000150:complications / Q000188:drug therapy*; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006497:Heparan Sulfate; D006801:Humans; D008297:Male; D008875:Middle Aged; D013923:Thromboembolism / Q000188:drug therapy* / Q000209:etiology
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans; D006497:Heparan Sulfate; C035838:danaparoid